Collaboration Agreement between Intensity TherapeuticsCollaboration Agreement • August 8th, 2024 • Intensity Therapeutics, Inc. • Biological products, (no disgnostic substances)
The trial SAKK 66/22 “Intratumoral INT230-6 followed by neoadjuvant Pembrolizumab and chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK”
